In this issue:
Enfortumab vedotin elicits a survival advantage in pretreated advanced urothelial cancer
Frontline nivolumab plus cabozantinib superior to sunitinib for advanced RCC
KEYNOTE-427 trial shows antitumour activity for PD-1 blockade in advanced clear cell RCC
Front-line pembrolizumab shows antitumour activity in advanced non-clear cell RCC
Predicting outcomes in men with metastatic nonseminomatous germ cell tumours
Nivolumab/ipilimumab combination elicits a response in BUTCVH
Intermediate/poor risk patients with testicular cancer at increased risk of morbidity following RPLND
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated CRPC
Fracture risk in men with metastatic prostate cancer treated with radium-223
Docetaxel addition to ADT provides a benefit regardless of age in hormone-sensitive prostate cancer
Please login below to download this issue (PDF)